scholarly journals Non-small cell lung cancer in elderly – retrospective study comparing single-agent versus doublet chemotherapy

2020 ◽  
Vol 17 (2) ◽  
Author(s):  
Élia Cipriano ◽  
◽  
Helena Magalhães ◽  
Fernanda Estevinho ◽  
◽  
...  
Keyword(s):  
Lung Cancer ◽  
Retrospective Study ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Advanced Disease ◽  
Single Agent ◽  
Locally Advanced ◽  
Small Cell ◽  
Small Cell Lung ◽  
Doublet Chemotherapy

Background: In non -small cell lung cancer (NSCLC) elderly patients with advanced disease and without driver mutations, questions remain if they benefit from doublet chemotherapy (ChT) or single -agent ChT. Methods: A retrospective study characterizing elderly NSCLC patients with advanced disease. The primary endpoint was overall survival (OS) after doublet ChT and single -agent ChT, calculated using Kaplan -Meier method and Log Rank test. Results: Forty -six patients with locally advanced or metastatic disease were treated with ChT (22 with platinum- -based doublet ChT and 24 with single -agent ChT). With a median follow -up of 26.6 months (mo.), the median OS was 8.4 mo. in doublet ChT and 7.0 mo. in single‑agent ChT, p=0.441. Conclusions: There were no statistically significant differences in survival between platinum -based doublet and monotherapy ChT in our studied population.

Randomized, Double-Blind, Placebo-Controlled Phase II Study of Single-Agent Oral Talactoferrin in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer That Progressed After Chemotherapy

2011 ◽  
Vol 29 (31) ◽  
pp. 4129-4136 ◽  
Author(s):  
Purvish M. Parikh ◽  
Ashok Vaid ◽  
Suresh H. Advani ◽  
Raghunadharao Digumarti ◽  
Jayaprakash Madhavan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Patient Population ◽  
Single Agent ◽  
Locally Advanced ◽  
Anticancer Therapy ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung

Purpose To investigate the activity and safety of oral talactoferrin (TLF) in patients with stages IIIB to IV non–small-cell lung cancer (NSCLC) for whom one or two prior lines of systemic anticancer therapy had failed. Patients and Methods Patients (n = 100) were randomly assigned to receive either oral TLF (1.5 g in 15 mL phosphate-based buffer) or placebo (15 mL phosphate-based buffer) twice per day in addition to supportive care. Oral TLF or placebo was administered for a maximum of three 14-week cycles with dosing for 12 consecutive weeks followed by 2 weeks off. The primary objective was overall survival (OS) in the intent-to-treat (ITT) patient population. Secondary objectives included progression-free survival (PFS), disease control rate (DCR), and safety. Results TLF was associated with improvement in OS in the ITT patient population, meeting the protocol-specified level of significance of a one-tailed P = .05. Compared with the placebo group, median OS increased by 65% in the TLF group (3.7 to 6.1 months; hazard ratio, 0.68; 90% CI, 0.47 to 0.98; P = .04 with one-tailed log-rank test). Supportive trends were also observed for PFS and DCR. TLF was well tolerated and, generally, there were fewer adverse events (AEs) and grade ≥ 3 AEs reported in the TLF arm. AEs were consistent with those expected in late-stage NSCLC. Conclusion TLF demonstrated an apparent improvement in OS in patients with stages IIIB to IV NSCLC for whom one or two prior lines of systemic anticancer therapy had failed and was well tolerated. These results should be confirmed in a global phase III trial.

scholarly journals Treatment patterns and survival in patients with ALK-positive non-small-cell lung cancer: a Canadian retrospective study

2016 ◽  
Vol 23 (6) ◽  
pp. 589 ◽  
Author(s):  
S. Kayaniyil ◽  
M. Hurry ◽  
J. Wilson ◽  
P. Wheatley-Price ◽  
B. Melosky ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Retrospective Study ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Locally Advanced ◽  
Treatment Patterns ◽  
Additional Treatment ◽  
Small Cell ◽  
Small Cell Lung ◽  
Alk Positive

Background Crizotinib was the first agent approved for the treatment of anaplastic lymphoma kinase (ALK)– positive (+) non-small-cell lung cancer (nsclc), followed by ceritinib. However, patients eventually progress or develop resistance to crizotinib. With limited real-world data available, the objective of the present work was to evaluate treatment patterns and survival after crizotinib in patients with locally advanced or metastatic ALK+ nsclc in Canada.Methods In this retrospective study at 6 oncology centres across Canada, medical records of patients with locally advanced or metastatic ALK+ nsclc were reviewed. Demographic and clinical characteristics, treatments, and outcomes data were abstracted. Analyses focused on patients who discontinued crizotinib treatment.Results Of the 97 patients included, 9 were crizotinib-naïve, and 39 were still receiving crizotinib at study end. The 49 patients who discontinued crizotinib treatment were included in the analysis. Of those 49 patients, 43% received ceritinib at any time, 20% subsequently received systemic chemotherapy only (but never ceritinib), and 37% received no further treatment or died before receiving additional treatment. Median overall survival from crizotinib discontinuation was shorter in patients who did not receive ceritinib than in those who received ceritinib (1.7 months vs. 20.4 months, p < 0.001). In a multivariable analysis, factors associated with poorer survival included lack of additional therapies (particularly ceritinib), male sex, and younger age, but not smoking status; patients of Asian ethnicity showed a nonsignificant trend toward improved survival.Conclusions A substantial proportion of patients with ALK+ nsclc received no further treatment or died before receiving additional treatment after crizotinib. Treatment with systemic agents was associated with improved survival, with ceritinib use being associated with the longest survival. 

Sign in / Sign up

Export Citation Format

Share Document